; and (ii) in addition to the information required under subparagraphs (F), (G), and (H) of paragraph (1), such average wholesale acquisition cost, average net price, and total rebates and other payments, described in each of such subparagraphs, respectively, with respect to the calendar year immediately preceding the calendar year for which such information is required to be reported under such subparagraphs (F), (G), and (H). (B) Subsequently marketed drugs With respect to a prescription drug that is first marketed after December 31, 2020, each manufacturer of such a drug shall submit the information required under subparagraphs (A) through (E) of paragraph (1) not later than 60 days after the date on which the drug is first marketed, and shall submit annual reports of all of the information required under paragraph (1) beginning on the first annual reporting date that is more than 30 days after the date on which the drug is first marketed. (b) Advance notification of prescription drug pricing changes (1) In general Each manufacturer of a prescription drug shall report to the Secretary, electronically, in such manner as the Secretary may require, any increase or decrease in the wholesale acquisition cost of a prescription drug not later than 30 days prior to the date on which the price change takes effect. (2) Content A price change report under paragraph (1) shall include— (A) the information required under subparagraphs (A), (B), (C), (D), and (F) of subsection (a)(1); (B) the wholesale acquisition cost per 30-day supply or typical course of treatment immediately prior to the price change; (C) the new wholesale acquisition cost per 30-day supply or typical course of treatment, when the change takes effect